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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To evaluate the efficacy of tailoring asthma medications based on exhaled nitric oxide (FeNO) for asthma related outcomes in children.
We will compare this with not using FeNO i.e. management based on clinical symptoms (with or without spirometry/peak flow) and/
or asthma guidelines.
B A C K G R O U N D
Description of the condition
Asthma is one of the most common chronic diseases in chil-
dren. Acute flare-ups (exacerbations) are common in children with
asthma and some require more intensive treatment in hospital.
Hospitalisations for asthma account for 12 to 21% (Anderson
2007; Akinbami 2009) of hospitalisations worldwide (Gupta
2006). Thus prevention of exacerbations, particularly severe ex-
acerbations, is one goal of good asthma management. The sec-
ond component in asthma management is monitoring of asthma
control (by subjective and objective measures) (BTS/SIGN 2014;
GINA 2014; National Asthma Council 2014). Subjective mea-
sures usually involve a series of questions used for clinical assess-
ment, diary cards and quality of life (QoL) questionnaires. Tradi-
tional objective methods include peak flow, spirometry and degree
of airway hyperresponsiveness (Zacharasiewicz 2005). Newer and
arguably more sensitive methods include measurement of airway
inflammation such as airway cellularity in induced sputum or frac-
tional exhaled nitric oxide (FeNO).
Airway inflammation associated with asthma can be eosinophilic
or neutrophilic (Douwes 2002). Arguably, asthma management
is best tailored in accordance to the type of airway inflamma-
tion, as corticosteroids is more beneficial in eosinophilic inflam-
mation (Wardlaw 2000); inhaled corticosteroids (ICS) reduce ex-
acerbations and improves symptoms and asthma control (Wardlaw
2000). There are several ways to quantify airway eosinophilic in-
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flammation, such as determining the percentage of eosinophils
in the sputum and FeNO. FeNO correlates with other markers
of asthma e.g. eosinophilia in induced sputum (Jatakanon 1998)
and bronchial reactivity in non-steroid treated subjects (Dupont
1998).
Description of the intervention
The principle of asthmamanagement is based on a step-up or step-
down regimen of asthma medications to reduce airway inflam-
mation, control symptoms and reduce exacerbations. Thus tailor-
ing of asthma medications in accordance to airway eosinophilic
levels may improve asthma control and/or reduce exacerbations.
Obtaining induced sputum samples and sputum analysis is labour
intensive and not widely available in most routine clinical settings.
Hypertonic saline, used to induce sputum may also temporarily
increase asthma symptoms (such as wheeze, cough and chest tight-
ness) and sputum is not always successfully obtained in young chil-
dren. Thus, measures of FeNO confer some advantage over mea-
surements of sputum eosinophils. However, assessment of FeNO
levels do not provide any data on non-eosinophilic inflammation
and the equipment required to measure FeNO is relatively expen-
sive.
FeNO levels can be measured using commercially available anal-
ysers. These analysers vary in several ways that include methods
of measurements (on-line or off-line), complexity, their set up,
calibration procedures, sampling tube design, measuring cham-
ber and the way expiratory flow is controlled (Muller 2005). The
stationary analysers measure FeNO by chemoluminescence whilst
the portable FeNO analysers measure FeNO using electrochem-
istry.
How the intervention might work
As FeNO is reflective of airway eosinophilia in some circum-
stances, FeNO can be considered as a biomarker. For asthma,
FeNO levels can be potentially used in children with asthma to:
• monitor airway eosinophilia
• verify the adherence to ICS, and
• predict upcoming asthma exacerbations.
Reduction of airway inflammation improves symptoms and
asthma control (Wardlaw 2000). Hence, the use of FeNO levels to
tailor asthma medications in children with asthma may improve
asthma control and/or reduce exacerbations.
Why it is important to do this review
ApreviousCochrane Review analysed adults and children together
(Petsky 2009). Given the clinical heterogeneity between children
and adults, rather than update that review, we plan to undertake
separate reviews for children and adults, this protocol focuses on
children and there will be a similar systematic review that includes
only adult participants.
A systematic review evaluating the efficacy of tailoring asthma in-
terventions based on FeNO levels will be useful to guide clini-
cal practice in children with asthma. Using FeNO routinely in
clinical practice adds to the burden of asthma care and resource
utilisation. On the other hand, routine use of FeNO to guide use
of asthma medications may improve asthma control and reduce
exacerbations and hospitalisations related to asthma.
O B J E C T I V E S
To evaluate the efficacy of tailoring asthma medications based on
exhaled nitric oxide (FeNO) for asthma related outcomes in chil-
dren. We will compare this with not using FeNO i.e. manage-
ment based on clinical symptoms (with or without spirometry/
peak flow) and/or asthma guidelines.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include randomised controlled trials (RCTs) comparing
adjustment of asthma medications based on exhaled nitric oxide
(FeNO) levels in comparison to those not using FeNO i.e. man-
agement based on clinical symptoms (with or without spirometry/
peak flow) and/or current asthma guidelines.
Types of participants
We will include children/adolescents with a diagnosis of asthma
according to a guideline defined criteria.
We will exclude participants with the following co-morbidities/
characteristics: eosinophilic bronchitis, asthma related to an un-
derlying lung disease such as bronchiectasis and chronic obstruc-
tive pulmonary disease (COPD), or diagnostic categories such as
’cough variant asthma’ and ’wheezy bronchitis’.
Types of interventions
We will include RCTs comparing adjustment of asthma medica-
tions based on FeNO levels versus control groups where FeNO
is not used to adjust asthma medications. Control group inter-
ventions may includes use of clinical symptoms (with or without
spirometry/peak flow) to guide adjustment of asthmamedications.
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Trials that included the use of other interventions will be included
if all participants had equal access to such interventions. We will
include trials of at least 12 weeks duration.
Types of outcome measures
Primary outcomes
Asthma exacerbations during follow-up. Defined as:
1. Number of participants who had one or more exacerbations
over the study period
2. Number of exacerbations per 52 weeks (exacerbation rate)
3. Severe exacerbations requiring oral corticosteroids
4. Severe exacerbation requiring hospitalisations
Secondary outcomes
1. Objective measurements of asthma control (FEV1, peak
flow, airway hyper-responsiveness)
2. FeNO level
3. Symptoms of asthma as reported in asthma quality of life
score
4. Inhaled corticosteroid dose at final visit
Reporting one of more of the outcomes listed here in the trial is
not an inclusion criterion for the review.
Search methods for identification of studies
Electronic searches
We will identify trials from the Cochrane Airways Group’s Spe-
cialisedRegister (CAGR), which ismaintained by the Trials Search
Co-ordinator for the Group. The Register contains trial reports
identified through systematic searches of bibliographic databases
including the Cochrane Central Register of Controlled Trials
(CENTRAL), MEDLINE, EMBASE, CINAHL, AMED, and
PsycINFO, and handsearching of respiratory journals andmeeting
abstracts (please see Appendix 1 for further details). We will search
all records in the CAGR using the search strategy in Appendix 2.
We will also conduct a search of
ClinicalTrials.gov (www.ClinicalTrials.gov) and the WHO trials
portal (www.who.int/ictrp/en/). We will search all databases from
their inception to the present, and we will impose no restriction
on language of publication. We will include studies reported as
full-text, those published as abstract only, and unpublished data.
Searching other resources
We will check reference lists of all primary studies and review ar-
ticles for additional references. We will search relevant manufac-
turers’ websites for trial information.
We will search for errata or retractions from included studies pub-
lished in full-text on PubMed (www.ncbi.nlm.nih.gov/pubmed)
and report the date this was done within the review.
Data collection and analysis
Selection of studies
Two authors (HP, KK) will independently screen titles and ab-
stracts for inclusion of all the potential studies we identify as a re-
sult of the search and code them as ’retrieve’ (eligible or potentially
eligible/unclear) or ’do not retrieve’. We will retrieve the full-text
study reports/publication and two review authors (HP, KK) will
independently screen the full-text and identify studies for inclu-
sion, and identify and record reasons for exclusion of the ineligible
studies. We will resolve any disagreement through discussion or, if
required, we will consult a third person (AC).We will identify and
exclude duplicates and collate multiple reports of the same study
so that each study rather than each report is the unit of interest
in the review. We will record the selection process in sufficient
detail to complete a PRISMA flow diagram and ’Characteristics
of excluded studies’ table.
Data extraction and management
We will use a data collection form for study characteristics and
outcome data which has been piloted on at least one study in the
review. One review author (HP) will extract study characteristics
from included studies. A second review author (KK) will spot-
check study characteristics for accuracy against the trial report.We
will extract the following study characteristics.
1. Methods: study design, total duration of study, details of
any ’run in’ period, number of study centres and location, study
setting, withdrawals, and date of study.
2. Participants: N, mean age, age range, gender, severity of
condition, diagnostic criteria, baseline lung function, smoking
history, inclusion criteria, and exclusion criteria.
3. Interventions: intervention, comparison, concomitant
medications, and excluded medications.
4. Outcomes: primary and secondary outcomes specified and
collected, and time points reported.
5. Notes: funding for trial, and notable conflicts of interest of
trial authors.
Two review authors (HP, KK) will independently extract outcome
data from included studies from current search. We will note in
the ’Characteristics of included studies’ table if outcome data was
not reported in a usable way. We will resolve disagreements by
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consensus or by involving a third person (AC). One review author
(HP) will transfer data into the Review Manager (RevMan) file.
We will double-check that data is entered correctly by comparing
the data presented in the systematic review with the study reports.
Assessment of risk of bias in included studies
Two review authors (HP, KK) will independently assess risk of
bias for each new study using the criteria outlined in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
We will resolve any disagreements by discussion or by involving
another author (AC). We will assess the risk of bias according to
the following domains.
1. Random sequence generation.
2. Allocation concealment.
3. Blinding of participants and personnel.
4. Blinding of outcome assessment.
5. Incomplete outcome data.
6. Selective outcome reporting.
7. Other bias.
We will grade each potential source of bias as high, low or unclear
and provide a quote from the study report together with a justifi-
cation for our judgment in the ’Risk of bias’ table. We will sum-
marise the risk of bias judgements across different studies for each
of the domains listed. We will consider blinding separately for dif-
ferent key outcomes where necessary (e.g. for unblinded outcome
assessment, risk of bias for all-cause mortality may be very differ-
ent than for a patient reported pain scale). Where information on
risk of bias relates to unpublished data or correspondence with a
trialist, we will note this in the ’Risk of bias’ table.
When considering treatment effects, we will take into account the
risk of bias for the studies that contribute to that outcome.
Assesment of bias in conducting the systematic
review
We will conduct the review according to this published protocol
and report any deviations form it in the ’Differences between pro-
tocol and review’ section of the systematic review.
Measures of treatment effect
We will analyse dichotomous data as odds ratios and continuous
data as mean difference (MD) or standardised mean difference
(SMD). We will enter data presented as a scale with a consistent
direction of effect.
We will undertake meta-analyses only where this is meaningful i.e.
if the treatments, participants and the underlying clinical question
are similar enough for pooling to make sense.
We will narratively describe skewed data reported as medians and
interquartile ranges.
Where multiple trial arms are reported in a single trial, we will
include only the relevant arms. If two comparisons (e.g. drug A
versus placebo and drug B versus placebo) are combined in the
same meta-analysis, we will halve the control group to avoid dou-
ble-counting.
Unit of analysis issues
For dichotomous data, we will report the proportion of partici-
pants contributing to each outcome in comparison with the total
number randomised. For rate ratios of common events whereby
one participant may have more than one event, generic inverse
variance analysis (GIV), will be used. The rate ratios will be taken
from the published papers and the standard errors calculated from
confidence intervals or P values published in the papers. For cross-
over studies, mean treatment differences will be calculated from
raw data, and variances extracted or imputed and entered as fixed
effects (GIV) outcome, to provide summary weighted differences
and 95% confidence intervals (95%CI).
Dealing with missing data
We will contact investigators or study sponsors in order to verify
key study characteristics and obtain missing numerical outcome
data where possible (e.g. when a study is identified as abstract
only). Where this is not possible, and the missing data are thought
to introduce serious bias, we will explore the impact of including
such studies in the overall assessment of results by a sensitivity
analysis.
Assessment of heterogeneity
Any heterogeneity between the study results will be described and
tested to see if it reaches statistical significance using a chi-squared
test. The 95%CI estimated using a random effects model will be
included whenever there are concerns about statistical heterogene-
ity. Heterogeneity is considered significant when the P value is <
0.10 (Higgins 2011).We will use the I² statistic to measure hetero-
geneity among the trials in each analysis. If we identify substantial
heterogeneity we will report it and explore possible causes by pre-
specified subgroup analysis.
Assessment of reporting biases
If we are able to pool more than 10 trials, we will create and exam-
ine a funnel plot to explore possible small study and publication
biases.
Data synthesis
The results from studies that meet the inclusion criteria and re-
ported any of the outcomes of interest will be included in the
subsequent meta-analyses. The summary weighted risk ratio and
95%CI (fixed effects model) will be calculated Review Manager
(RevMan). For rate ratios of common events whereby one subject
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may havemore than one event, GIVwill be utilised. The rate ratios
will be taken from the published papers and the standard errors
calculated from CIs or P values published in the papers. For cross-
over studies, mean treatment differences will be calculated from
raw data, and variances extracted or imputed and entered as fixed
effects GIV outcome, to provide summary weighted differences
and 95%CI. Numbers needed to treat (NNT) will be calculated
from the pooled OR and its 95%CI applied to a specified baseline
risk using an online calculator (Cates 2008). The outcome indices
will be assumed to be normally distributed continuous variables
so the MD in outcomes could be estimated. If studies report out-
comes using different measurement scales, the SMD will be esti-
mated.
Summary of findings (SoF) table
We will create a ’Summary of findings’ table using the following
outcomes:
1. Number of participants who had one or more exacerbations
over the study period,
2. Number of exacerbations per 52 weeks,
3. ICS dose at final visit
The SoF table in the previous combined review (Petsky 2009) will
be amended to reflect new data and restricted to the inclusion cri-
teria. We will use the five GRADE considerations (study limita-
tions, consistency of effect, imprecision, indirectness and publica-
tion bias) to assess the quality of a body of evidence as it relates to
the studies which contribute data to the meta-analyses for the pre-
specified outcomes. We will use methods and recommendations
described in Section 8.5 and Chapter 12 of the Cochrane Hand-
book for Systematic Reviews of Interventions (Higgins 2011) using
GRADEpro software (GRADEpro). We will justify all decisions
to down- or up-grade the quality of studies using footnotes and we
will make comments to aid reader’s understanding of the review
where necessary.
Subgroup analysis and investigation of heterogeneity
Subgroup analysis is planned for:
1. Basis for adjustment of ICS in the control group (guideline
driven monitoring versus non-guideline driven)
2. Use of spirometry or peak flow as an adjunctive monitoring
tool for adjustment of medications versus non-use of spirometry
or peak flow
3. Baseline ICS dose at commencement of intervention (low-
medium [<800 mcg/day budesonide equivalent] versus high dose
[800 mcg/day or more budesonide equivalent]
4. FeNO cut-offs for adjustment of medications (≤ 20 ppb
versus > 20 ppb)
5. FeNO cut-offs, based on presence of atopy
Sensitivity analysis
We plan to carry out the following sensitivity analyses.
1. Sensitivity analysis excluding studies with a high risk of bias
based on the ’Risk of bias’ assessment. Studies that do not have
adequate allocation concealment and sequence generation will be
removed.
2. Variation in the inclusion criteria. Studies that included
children not receiving ICS at recruitment will removed.
3. Differences in the medications used in the intervention and
comparison group. Studies that adjusted medications only for
one arm will be removed.
4. Analysis used random effects model
5. Analysis by “strategy received”. Studies with hierarchy
management protocols that only considered use of steroids for
each step (i.e. without consideration for using montelukast and/
or LABA at any point) will be removed.
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Appendix 1. Sources and search methods for the Cochrane Airways Group Specialised Register
(CAGR)
Electronic searches: core databases
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Database Frequency of search
CENTRAL (the Cochrane Library) Monthly
MEDLINE (Ovid) Weekly
Embase (Ovid) Weekly
PsycINFO (Ovid) Monthly
CINAHL (EBSCO) Monthly
AMED (EBSCO) Monthly
Hand-searches: core respiratory conference abstracts
Conference Years searched
AmericanAcademyofAllergy, Asthma and Immunology (AAAAI) 2001 onwards
American Thoracic Society (ATS) 2001 onwards
Asia Pacific Society of Respirology (APSR) 2004 onwards
British Thoracic Society Winter Meeting (BTS) 2000 onwards
Chest Meeting 2003 onwards
European Respiratory Society (ERS) 1992, 1994, 2000 onwards
International PrimaryCareRespiratoryGroupCongress (IPCRG) 2002 onwards
Thoracic Society of Australia and New Zealand (TSANZ) 1999 onwards
MEDLINE search strategy used to identify trials for the CAGR
Asthma search
1. exp Asthma/
2. asthma$.mp.
3. (antiasthma$ or anti-asthma$).mp.
4. Respiratory Sounds/
5. wheez$.mp.
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6. Bronchial Spasm/
7. bronchospas$.mp.
8. (bronch$ adj3 spasm$).mp.
9. bronchoconstrict$.mp.
10. exp Bronchoconstriction/
11. (bronch$ adj3 constrict$).mp.
12. Bronchial Hyperreactivity/
13. Respiratory Hypersensitivity/
14. ((bronchial$ or respiratory or airway$ or lung$) adj3 (hypersensitiv$ or hyperreactiv$ or allerg$ or insufficiency)).mp.
15. ((dust or mite$) adj3 (allerg$ or hypersensitiv$)).mp.
16. or/1-15
Filter to identify RCTs
1. exp “clinical trial [publication type]”/
2. (randomised or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
7. groups.ab,ti.
8. or/1-7
9. Animals/
10. Humans/
11. 9 not (9 and 10)
12. 8 not 11
The MEDLINE strategy and RCT filter are adapted to identify trials in other electronic databases.
Appendix 2. Search strategy to identify relevant trials from the CAGR
#1 AST:MISC1
#2 MeSH DESCRIPTOR Asthma Explode All
#3 asthma*:ti,ab
#4 #1 or #2 or #3
#5 MeSH DESCRIPTOR Nitric Oxide
#6 nitric* NEXT oxide*
#7 FeNO
#8 eNO
#9 “airway inflammation”
#10 “exhaled NO”
#11 biomarker*:ti,ab
#12 #5 or #6 or #7 or #8 or #9 or #10 or #11
#13 #4 and #12
[Note: in search line #1, MISC1 denotes the field in which the reference has been coded for condition, in this case, asthma]
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C O N T R I B U T I O N S O F A U T H O R S
Written by HP and AC. KK, JAK and CT reviewed the protocol.
D E C L A R A T I O N S O F I N T E R E S T
HP, AC, JAK, CT: Have conducted a RCT on this topic which will be included in the review.
KK: none known
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